Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development
Source: SeekingAlpha
2025-11-19 15:01:02 ET
The last time I spoke about Enanta Pharmaceuticals, Inc. ( ENTA ) it was in a Seeking Alpha article entitled "Enanta: Despite Primary Endpoint Miss Zelicapavir Could Benefit From Trial Design Change." I noted then that this company had failed to meet the primary endpoint of the phase 2b randomized RSVHR study, which was time to resolution of the lower respiratory tract disease [LRTD] of 4 symptoms....
Read the full article on Seeking Alpha
For further details see:
Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development
Enanta Pharmaceuticals Inc.
NASDAQ: ENTA
ENTA Trading
-1.78% G/L:
$13.23 Last:
29,667 Volume:
$13.63 Open:
ENTA Latest News
March 03, 2026 07:00:00 am
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
February 10, 2026 07:00:00 am
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
February 09, 2026 04:01:00 pm
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
ENTA Stock Data
$400,455,604
24,201,447
4.66%
34
N/A
Biotechnology & Life Sciences
Healthcare
US
Watertown
